Some videos you haven't seen yet, about GLP1 weight loss drugs.

There are a lot of good (and bad) resources out there on GLP1 Agonists and their usefulness for type 2 diabetes treatment and weight loss, and here at GLP1.guide our job is to put more of those resources in front of you.

Here are some we've found incredibly useful:

Harvard Medical School basic explanation of GLP1 (trials, efficacy)

This is a fantastic introductory video on the space, previous drugs that were approved for weight management, along with how GLP1 works and why it is different.

Peter Attia's Pros & Cons to weight loss drugs and Metformin

Here at GLP1.guide, we try to avoid being biased against "health influencers", and Peter's track record of calm, research based assertions and simple-to-understand advice increases our trust in his judgement. While he does indeed have much to sell, his processing of research and experience with patients is certainly worth taking into consideration.

Dr. Kate Lyzenga-Dean's idea of Natural GLP-1 Agonists

Despite any possible whiff of homeopathy, Dr. Lyzenga-Dean's video is packed with research-supported facts and introduces some foods that are expected to boost the natural production of GLP1 in the gut.

The list of studies she cites is extensive and useful:

Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review

The positive influences of glucagon-like peptide-1 (GLP-1) on blood glucose homeostasis, appetite sensations, and food intake provide a strong rationale for its therapeutic potential in the nutritional management of obesity and type 2 diabetes.To summarize…

PubMed Central (PMC)Alexandra M. Bodnaruc

Adverse Effects of GLP-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D). However, the use of this relatively…

PubMed Central (PMC)Theodosios D. Filippatos

STEP1 Trial

https://www.researchgate.net/publication/40038578_Modulation_of_glucagon-like_peptide-1_release_by_berberine_In_vivo_and_in_vitro_studies

The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis

Cardiovascular disease (CVD) is a major concern today. Herbal medicine is one helping way to control CVD risks. One conclusive of herbal medicine is Berberine (BBR) and converse about it still exists, to clarify this issue, this meta-analysis was performed. PubMed/Medline, Scopus, and Web of Science were searched for RCTs in adults on the effect of BBR supplementation on CVD risk factors up to July 2022. The pooled results showed BBR significantly reduced triglyceride (WMD = −23.70 mg/dl; 95%CI −30.16, −17.25; P < 0.001), total cholesterol (WMD = −20.64 mg/dl; 95%CI −23.65, −17.63; P < 0.001), low-density lipoprotein WMD = −9.63 mg/dl; 95%CI, −13.87, −5.39; P < 0.001), fasting blood glucose (FBG) (WMD = −7.74 mg/dl; 95%CI −10.79, −4.70; P < 0.001), insulin (WMD = −3.27 mg/dl; 95%CI −4.46,−2.07; P < 0.001), HbA1c (WMD = −0.45%; 95%CI −0.68, −0.23; P < 0.001), HOMA-IR (WMD = −1.04; 95%CI −1.55, −0.52; P < 0.001), systolic blood pressure (WMD = −5.46 mmHg; 95%CI −8.17, −2.76; P < 0.001), weight (WMD = −0.84; 95%CI −1.34,−0.34; P < 0.001), body mass index (WMD = −0.25 kg/m2; 95%CI −0.46, −0.04; P = 0.020), while increased high-density lipoprotein (HDL) (WMD = 1.37 mg/dl; 95%CI 0.41,2.23; P = 0.005). The optimal dose of BBR was 1 g/day for TG, TC, and weight, 1.8 g/day for insulin and HOMA-IR, and 5 g/day for HDL. FBG’s most efficient time frame was 40 weeks from the beginning of supplementation, whereas DBP and waist circumference was 50 weeks. In conclusion, the lipid profile…

FrontiersLILIA CASTILLO-MARTINEZ

The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis

Cardiovascular disease (CVD) is a major concern today. Herbal medicine is one helping way to control CVD risks. One conclusive of herbal medicine is Berberine (BBR) and converse about it still exists, to clarify this issue, this meta-analysis was performed. PubMed/Medline, Scopus, and Web of Science were searched for RCTs in adults on the effect of BBR supplementation on CVD risk factors up to July 2022. The pooled results showed BBR significantly reduced triglyceride (WMD = −23.70 mg/dl; 95%CI −30.16, −17.25; P < 0.001), total cholesterol (WMD = −20.64 mg/dl; 95%CI −23.65, −17.63; P < 0.001), low-density lipoprotein WMD = −9.63 mg/dl; 95%CI, −13.87, −5.39; P < 0.001), fasting blood glucose (FBG) (WMD = −7.74 mg/dl; 95%CI −10.79, −4.70; P < 0.001), insulin (WMD = −3.27 mg/dl; 95%CI −4.46,−2.07; P < 0.001), HbA1c (WMD = −0.45%; 95%CI −0.68, −0.23; P < 0.001), HOMA-IR (WMD = −1.04; 95%CI −1.55, −0.52; P < 0.001), systolic blood pressure (WMD = −5.46 mmHg; 95%CI −8.17, −2.76; P < 0.001), weight (WMD = −0.84; 95%CI −1.34,−0.34; P < 0.001), body mass index (WMD = −0.25 kg/m2; 95%CI −0.46, −0.04; P = 0.020), while increased high-density lipoprotein (HDL) (WMD = 1.37 mg/dl; 95%CI 0.41,2.23; P = 0.005). The optimal dose of BBR was 1 g/day for TG, TC, and weight, 1.8 g/day for insulin and HOMA-IR, and 5 g/day for HDL. FBG’s most efficient time frame was 40 weeks from the beginning of supplementation, whereas DBP and waist circumference was 50 weeks. In conclusion, the lipid profile…

FrontiersLILIA CASTILLO-MARTINEZ

While Semaglutide (Ozempic, Wegovy, etc) and other GLP1 Agonists are normally our main focus, Dr. Lyzenga-Dean's assesment of the risks of these drugs (and the requirement to stay on them long term) is accurate, so considering natural GLP1-production boosting foods makes sense, especially when considering those who are not managing type 2 diabetes.

📬 Get the latest GLP1 news straight to your inbox